| Jesse Gleckman, | |
|
20 Woodruff Ave, Narragansett, RI 02882-3423 | |
| (401) 792-7179 | |
| Not Available |
| Full Name | Jesse Gleckman |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 20 Woodruff Ave, Narragansett, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467869875 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH05116 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jesse Gleckman, 20 Woodruff Ave, Narragansett, RI 02882-3423 Ph: () - | Jesse Gleckman, 20 Woodruff Ave, Narragansett, RI 02882-3423 Ph: (401) 792-7179 |
News Archive
Researchers at Lund University in Sweden have taken an important step on the road to understanding the underlying mechanism of how and why animals can feel pain in connection with cold or heat. However, according to the study, temperature is just one triggering factor – horseradish, mustard, cinnamon and wasabi have a similar effect.
A report published on 30 November 2018 in Preventive Medicine reveals that a stunning 17 percent of children could possibly be affected by alcohol exposure during their intrauterine life. This refers to a group of lifelong conditions caused by prenatal drinking, called fetal alcohol spectrum disorder (FASD).
The median profit margin of U.S. hospitals increased from 0.17 percent in the third quarter of 2008 to 3.1 percent in the first quarter of 2009, according to an analysis of hospital finances published today by Thomson Reuters.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.
› Verified 8 days ago
Cynthia T Cruser, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 Woodruff Ave, Narragansett, RI 02882 Phone: 401-741-8415 | |
Christine Markut, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Boston Neck Rd, Narragansett, RI 02882 Phone: 401-783-1753 | |
Casey Adams, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 91 Point Judith Rd, Narragansett, RI 02882 Phone: 401-783-7768 | |
Dr. Christine Barabas, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 Woodruff Ave, Rite Aid Pharmacy, Narragansett, RI 02882 Phone: 401-792-7179 | |
Dr. Stacey Ellen Kostarides, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 Woodruff Ave, Narragansett, RI 02882 Phone: 401-792-7179 Fax: 401-792-7184 | |
Cassandra Couture, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Boston Neck Rd, Narragansett, RI 02882 Phone: 401-783-1753 | |
Linda Ann Carver, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 Woodruff Ave, Narragansett, RI 02882 Phone: 401-792-7179 Fax: 401-792-7184 |